A2B530 Harnesses Unique Mechanism of Action to Integrate CAR T in Solid Tumors

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.

Related Keywords

Massachusetts ,United States ,Tampa ,Florida ,Boston ,New York ,Kedar Kirtane ,Dianem Simeone ,Department Of Head ,Perlmutter Cancer Center ,Society For Immunotherapy Of Cancer ,Pancreatic Cancer Center ,Endocrine Oncology At Moffitt Cancer Center ,Neck Endocrine Oncology ,Moffitt Cancer Center ,Annual Meeting ,Tmodt Cell ,Accessed April ,Cart Cell Therapies Observed In Patients With Hematologic Malignancies ,Basecamp 1 Trial ,Patients With Advanced Solid Tumors ,Everest Trial ,